Survival outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer patients.

ABSTRACT:

Background

Neoadjuvant chemotherapy (NACT) has been widely used in breast cancer patients. The aim of the study was to compare survival outcomes between breast cancer patients receiving NACT, with and without complete pathologic response (pCR), and those receiving adjuvant chemotherapy (ACT).

Methods

Based on the Surveillance, Epidemiology, and End Results database, we conducted a population-based cohort study including 48 350 breast cancer patients, 15 525 of whom with pCR after NACT, and 124 202 patients after ACT during the period of 2010-2021. In comparison with patients in ACT group, we assessed hazard ratios (HRs) of breast cancer-specific and overall mortality among individuals in NACT using Cox regression.

Results

During the period of follow-up (median 5 years

SUBMITTER: Wang C 

PROVIDER: S-EPMC12623009 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature